<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">periodontology</journal-id><journal-title-group><journal-title xml:lang="ru">Пародонтология</journal-title><trans-title-group xml:lang="en"><trans-title>Parodontologiya</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1683-3759</issn><issn pub-type="epub">1726-7269</issn><publisher><publisher-name>Russian Periodontal Association (RPA)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33925/1683-3759-2023-784</article-id><article-id custom-type="elpub" pub-id-type="custom">periodontology-784</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИССЛЕДОВАНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH</subject></subj-group></article-categories><title-group><article-title>Оценка риска малигнизации лейкоплакии слизистой оболочки рта на основе показателей убиквитин-протеасомной системы</article-title><trans-title-group xml:lang="en"><trans-title>Risk assessment of oral leukoplakia malignant transformation based on the ubiquitin-proteasome system indicators</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5899-3872</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Михалев</surname><given-names>Д. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Mikhalev</surname><given-names>D. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михалев Дмитрий Евгеньевич, аспирант кафедры стоматологии</p><p>Томск</p></bio><bio xml:lang="en"><p>Dmitry E. Mikhalev, DMD, PhD Student, Department of Dentistry</p><p>Tomsk</p></bio><email xlink:type="simple">dm199412@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4748-4175</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Байдик</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Baydik</surname><given-names>O. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Байдик Ольга Дмитриевна, доктор медицинских наук, профессор, заведующая кафедрой стоматологии</p><p>Томск</p></bio><bio xml:lang="en"><p>Olga D. Baidik, DMD, PhD, DSc, Professor, Head of the Department of Dentistry</p><p>Tomsk</p></bio><email xlink:type="simple">olgabajdik@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0947-8778</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кондакова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kondakova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кондакова Ирина Викторовна, доктор медицинских наук, профессор, заведующая лабораторией биохимии опухолей</p><p>Томск</p></bio><bio xml:lang="en"><p>Irina V. Kondakova, MD, PhD, DSc, Professor, Head of the Laboratory of Tumour Biochemistry</p><p>Tomsk</p></bio><email xlink:type="simple">kondakova@oncology.tomsk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1555-050X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мухамедов</surname><given-names>М. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Mukhamedov</surname><given-names>M. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мухамедов Марат Рафкатович, доктор медицинских наук, ведущий научный сотрудник отделения опухолей головы и шеи</p><p>Томск</p></bio><bio xml:lang="en"><p>Marat R. Muhamedov, MD, PhD, DSc, Leading Researcher, Department of Head and Neck Tumours</p><p>Tomsk</p></bio><email xlink:type="simple">muhamedov@oncology.tomsk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт онкологии, Томский национальный исследовательский  медицинский центр Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cancer Research Institute, Tomsk National Research Medical Center оf the Russian Academy of Science</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>16</day><month>08</month><year>2023</year></pub-date><volume>28</volume><issue>3</issue><issue-title>Принято в печать</issue-title><fpage>276</fpage><lpage>285</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Михалев Д.Е., Байдик О.Д., Кондакова И.В., Мухамедов М.Р., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Михалев Д.Е., Байдик О.Д., Кондакова И.В., Мухамедов М.Р.</copyright-holder><copyright-holder xml:lang="en">Mikhalev D.E., Baydik O.D., Kondakova I.V., Mukhamedov M.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.parodont.ru/jour/article/view/784">https://www.parodont.ru/jour/article/view/784</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Убиквитин-протеасомная система контролирует активность и стабильность множества клеточных белков, влияющих на клеточный гомеостаз посредством регуляции сигнальных каскадов. Активность данной системы связана с возникновением и прогрессированием плоскоклеточного рака полости рта, так как специфический протеолиз большинства внутриклеточных протеинов, участвующих в патогенезе рака, происходит с помощью вышеупомянутой системы.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включен 61 пациент (28 мужчин и 33 женщины) в возрасте от 21 до 75 лет. Химотрипсинподобную и каспазаподобную активности циркулирующих и внутриклеточных протеасом определяли в сыворотке крови и биоптатах, взятых со слизистой оболочки рта по гидролизу соответствующего флуорогенного олигопептида на многорежимном микропланшетном ридере-имиджере Cytation1 при длине волны возбуждения 360 нм и эмиссии 460 нм, удельную активность протеасом выражали в единицах активности.</p></sec><sec><title>Результаты</title><p>Результаты. Значение удельной химотрипсинподобной активности циркулирующих протеасом при негомогенной лейкоплакии и плоскоклеточном раке полости рта были в 1,76 (p &lt; 0,001) раза и в 2,27 (p &lt; 0,001) раза выше относительно группы сравнения. При попарном сравнении признаков наблюдалась статистически значимая разница химотрипсинподобной активности между группами негомогенной и гомогенной лейкоплакии (p &lt; 0,001), негомогенной лейкоплакии и плоскоклеточного рака полости рта (p = 0,04). Значения удельной химотрипсинподобной и каспазоподобной активностей внутриклеточных протеасом в биоптатах взятых с патологического очага в группах гомогенной, негомогенной лейкоплакии и плоскоклеточного рака полости рта были в 1,6, 2,38, 3 (р = 0,002, p = 0,004, p = 0,03) и 1,5, 2,8 и 3,3 (p = 0,003, p = 0,012, p &lt; 0,001) раза выше по сравнению с группой сравнения.</p></sec><sec><title>Заключение</title><p>Заключение. Предложенная логит-модель для оценки риска малигнизации лейкоплакии слизистой оболочки рта на основе показателей убиквитин-протеасомной системы позволяет повысить качество диагностики данной патологии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. The ubiquitin-proteasome system controls the activity and stability of various cellular proteins that affect cellular homeostasis by the regulation of signalling cascades. The system activity is associated with the onset and progression of oral squamous cell carcinoma, as the system participates in the specific proteolysis of most intracellular proteins involved in cancer pathogenesis.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 61 patients (28 men and 33 women) aged 21 to 75 y.o. The study determined chymotrypsin-like (CTL) and caspase-like (CL) activities of circulating and intracellular proteasomes in blood serum and biopsy specimens taken from the oral mucosa by hydrolysis of the corresponding fluorogenic oligopeptide on a «Cytation1» multi-mode microplate reader-imager at an excitation wavelength of 360 nm and an emission of 460 nm, the specific activity of the proteasomes was expressed in units of activity.</p></sec><sec><title>Results</title><p>Results. The value of the specific chymotrypsin-like activity of circulating proteasomes in non-homogeneous leukoplakia and oral squamous cell carcinoma was 1.76 (p &lt; 0.001) times and 2.27 (p &lt; 0.001) times higher relative to the comparison group. Pairwise comparison of signs showed a statistically significant difference in chymotrypsinlike activity between the groups of non-homogeneous and homogeneous leukoplakia (p &lt; 0.001), non-homogeneous leukoplakia and oral squamous cell carcinoma (p = 0.04). The values of specific chymotrypsin-like and caspase-like activities of intracellular proteasomes in biopsy specimens taken from the pathological focus in the groups of homogeneous, non-homogeneous leukoplakia and squamous cell carcinoma of the oral cavity were 1.6, 2.38, 3 (p = 0.002, p = 0.004, p = 0.03) and 1.5, 2.8 and 3.3 (p = 0.003, p = 0.012, p &lt; 0.001) times higher compared to the control group.</p></sec><sec><title>Conclusion</title><p>Conclusion. The proposed logit model for risk assessment of oral leukoplakia malignant transformation, based on the indicators of the ubiquitin-proteasome system, can improve the quality of diagnosis.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>убиквитин-протеасомная система</kwd><kwd>лейкоплакия и плоскоклеточный рак полости рта</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ubiquitin-proteasome system</kwd><kwd>leukoplakia and oral squamous cell carcinoma</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Yactayo-Alburquerque MT, Alen-Méndez ML, Azañedo D, Comandé D, Hernández-Vásquez A. Impact of oral diseases on oral health-related quality of life: A systematic review of studies conducted in Latin America and the Caribbean. PLoS One. 2021;16(6):e0252578. doi: 10.1371/journal.pone.0252578</mixed-citation><mixed-citation xml:lang="en">Yactayo-Alburquerque MT, Alen-Méndez ML, Azañedo D, Comandé D, Hernández-Vásquez A. Impact of oral diseases on oral health-related quality of life: A systematic review of studies conducted in Latin America and the Caribbean. PLoS One. 2021;16(6):e0252578. doi: 10.1371/journal.pone.0252578</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mulla M. Impact of Oral Diseases and Conditions on Oral Health-Related Quality of Life: A Narrative Review of Studies Conducted in the Kingdom of Saudi Arabia. Cureus. 2021;13(9):e18358. doi: 10.7759/cureus.18358</mixed-citation><mixed-citation xml:lang="en">Mulla M. Impact of Oral Diseases and Conditions on Oral Health-Related Quality of Life: A Narrative Review of Studies Conducted in the Kingdom of Saudi Arabia. Cureus. 2021;13(9):e18358. doi: 10.7759/cureus.18358</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Peres MA, Macpherson LMD, Weyant RJ, et al. Oral diseases: a global public health challenge. Lancet. 2019;394(10194):249-260. doi: 10.1016/S0140-6736(19)31146-8</mixed-citation><mixed-citation xml:lang="en">Peres MA, Macpherson LMD, Weyant RJ, et al. Oral diseases: a global public health challenge. Lancet. 2019;394(10194):249-260. doi: 10.1016/S0140-6736(19)31146-8</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ивина АА, Родионов ВЭ, Бабиченко ИИ. Клиникоморфологические особенности лейкоплакии слизистой оболочки рта. Архив патологии. 2020;82(4):79–83. doi: 10.17116/patol20208204179</mixed-citation><mixed-citation xml:lang="en">Ivina AA, Rodionov VE, Babichenko II. Clinical and morphological features of leukoplakia of the oral mucosa. Pathology Archive. 2020;82(4):79–83 (In Russ.). doi: 10.17116/patol20208204179</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Межевикина ГС, Глухова ЕА. Современные методы диагностики предраковых и раковых изменений слизистой оболочки рта. Наука молодых (Eruditio Juvenium). 2018; 6(4):600-606. Режим доступа: https://cyberleninka.ru/article/n/sovremennye-metodydiagnostiki-predrakovyh-i-rakovyh-izmeneniy-slizistoyobolochki-rta</mixed-citation><mixed-citation xml:lang="en">Mezhevikina GS, Glukhova EA. Modern diagnostic methods precancerous and cancerous changes of the oral mucosa. Science of the Young (Eruditio Juvenium). 2018;6(4):600-606 (In Russ.). Available from: https://cyberleninka.ru/article/n/sovremennye-metodydiagnostiki-predrakovyh-i-rakovyh-izmeneniy-slizistoyobolochki-rta</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Brouns ER, Baart JA, Bloemena E, Karagozoglu H, van der Waal I. The relevance of uniform reporting in oral leukoplakia: definition, certainty factor and staging based on experience with 275 patients. Medicina oral, patología oral y cirugía bucal. 2013;18(1):e19-e26. doi: 10.4317/medoral.18756</mixed-citation><mixed-citation xml:lang="en">Brouns ER, Baart JA, Bloemena E, Karagozoglu H, van der Waal I. The relevance of uniform reporting in oral leukoplakia: definition, certainty factor and staging based on experience with 275 patients. Medicina oral, patología oral y cirugía bucal. 2013;18(1):e19-e26. doi: 10.4317/medoral.18756</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Чойнзонов ЕЛ, Спирина ЛВ, Кондакова ИВ, Чижевская СЮ, Шишкин ДА, Кульбакин ДЕ. Прогностическая значимость определения активности протеасом в тканях плоскоклеточных карцином головы и шеи. Сибирский научный медицинский журнал. 2014;34 (4):103-108. Режим доступа: https://cyberleninka.ru/article/n/prognosticheskaya-znachimost-opredeleniya-aktivnosti-proteasom-vtkanyah-ploskokletochnyh-kartsinom-golovy-i-shei</mixed-citation><mixed-citation xml:lang="en">Choynzonov EL, Spirina LV, Kondakova IV, Chizhevskaya SYu, Shishkin DA, Kulbakin DE. Prognostic value of proteasome activity determination in squamous cell carcinomas of head and neck. Siberian scientific medical journal. 2014;34 (4):103-108 (In Russ.). Available from: https://cyberleninka.ru/article/n/prognosticheskaya-znachimost-opredeleniya-aktivnosti-proteasom-vtkanyah-ploskokletochnyh-kartsinom-golovy-i-shei</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Woo SB. Oral Epithelial Dysplasia and Premalignancy. Head Neck Pathology. 2019;13(3):423-439. doi: 10.1007/s12105-019-01020-6</mixed-citation><mixed-citation xml:lang="en">Woo SB. Oral Epithelial Dysplasia and Premalignancy. Head Neck Pathology. 2019;13(3):423-439. doi: 10.1007/s12105-019-01020-6</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammed F, Fairozekhan AT. Oral Leukoplakia. In: StatPearls. 2023. Режим доступа: https://www.ncbi.nlm.nih.gov/books/NBK442013/</mixed-citation><mixed-citation xml:lang="en">Mohammed F, Fairozekhan AT. Oral Leukoplakia. In: StatPearls. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK442013/</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bugshan A, Farooq I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Research. 2020;9:229. doi: 10.12688/f1000research.22941.1</mixed-citation><mixed-citation xml:lang="en">Bugshan A, Farooq I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Research. 2020;9:229. doi: 10.12688/f1000research.22941.1</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jang HH. Regulation of Protein Degradation by Proteasomes in Cancer. Journal of Cancer Prevention. 2018;23(4):153-161. doi: 10.15430/JCP.2018.23.4.153</mixed-citation><mixed-citation xml:lang="en">Jang HH. Regulation of Protein Degradation by Proteasomes in Cancer. Journal of Cancer Prevention. 2018;23(4):153-161. doi: 10.15430/JCP.2018.23.4.153</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Сорокин АВ, Ким ЕР, Овчинников ЛП. Протеасомная система деградации и процессинга белков. Успехи биологической химии. 2009;49:3–76. Режим доступа: https://www.fbras.ru/wp-content/uploads/2017/10/Sorokin.pdf</mixed-citation><mixed-citation xml:lang="en">Sorokin AV, Kim ER, Ovchinnikov LP. Proteasome system of protein degradation and processing. Advances in biological chemistry. 2009;49:3–76 (In Russ.). Available from: https://www.fbras.ru/wp-content/uploads/2017/10/ Sorokin.pdf</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Voutsadakis IA. Ubiquitination and the ubiquitin – proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma. Anticancer Research. 2013;33(9):3527-3541. Режим доступа: https://ar.iiarjournals.org/content/33/9/3527.long</mixed-citation><mixed-citation xml:lang="en">Voutsadakis IA. Ubiquitination and the ubiquitin – proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma. Anticancer Research. 2013;33(9):3527-3541. Available from: https://ar.iiarjournals.org/content/33/9/3527.long</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Harshbarger W, Miller C, Diedrich C, Sacchettini J. Crystal structure of the human 20S proteasome in complex with carfilzomib. Structure. 2015;23(2):418-424. doi: 10.1016/j.str.2014.11.017</mixed-citation><mixed-citation xml:lang="en">Harshbarger W, Miller C, Diedrich C, Sacchettini J. Crystal structure of the human 20S proteasome in complex with carfilzomib. Structure. 2015;23(2):418-424. doi: 10.1016/j.str.2014.11.017</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Morozov AV, Karpov VL. Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer. Frontiers in Oncology. 2019;9:761. doi: 10.3389/fonc.2019.00761</mixed-citation><mixed-citation xml:lang="en">Morozov AV, Karpov VL. Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer. Frontiers in Oncology. 2019;9:761. doi: 10.3389/fonc.2019.00761</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Park J, Park E, Jung CK, et al. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC Cancer. 2016;16:247. doi: 10.1186/s12885-016-2285-2</mixed-citation><mixed-citation xml:lang="en">Park J, Park E, Jung CK, et al. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC Cancer. 2016;16:247. doi: 10.1186/s12885-016-2285-2</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zijl van F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutation Research. 2011;728(1-2):23-34. doi: 10.1016/j.mrrev.2011.05.002</mixed-citation><mixed-citation xml:lang="en">Zijl van F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutation Research. 2011;728(1-2):23-34. doi: 10.1016/j.mrrev.2011.05.002</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tang K, Liu J, Yang Z, et al. Microparticles mediate enzyme transfer from platelets to mast cells: a new pathway for lipoxin A4 biosynthesis. Biochemical and Biophysical Research Communications. 2010;400(3):432-436. doi: 10.1016/j.bbrc.2010.08.095</mixed-citation><mixed-citation xml:lang="en">Tang K, Liu J, Yang Z, et al. Microparticles mediate enzyme transfer from platelets to mast cells: a new pathway for lipoxin A4 biosynthesis. Biochemical and Biophysical Research Communications. 2010;400(3):432-436. doi: 10.1016/j.bbrc.2010.08.095</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan A, Farber EL, Rapoport AL, et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One. 2009;4(3):e4722. doi: 10.1371/journal.pone.0004722</mixed-citation><mixed-citation xml:lang="en">Yuan A, Farber EL, Rapoport AL, et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One. 2009;4(3):e4722. doi: 10.1371/journal.pone.0004722</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Юнусова НВ, Кондакова ИВ, Коломиец ЛА. Молчанов СВ Протеасомы и экзосомы при раке яичников: связь с особенностями клинического течения и прогнозом. Сибирский онкологический журнал. 2014;(4):53-59. Режим доступа: https://www.siboncoj.ru/jour/article/view/67/69</mixed-citation><mixed-citation xml:lang="en">Yunusova NV, Kondakova IV, Kolomiets LA. Molchanov SV Proteasomes and exosomes in ovarian cancer: relationship with clinical course and prognosis. Siberian journal of oncology. 2014;(4):53-59 (In Russ.). Available from: https://www.siboncoj.ru/jour/article/view/67/69</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Keller S, König AK, Marmé F, et al. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Letters. 2009;278(1):73-81. doi: 10.1016/j.canlet.2008.12.028</mixed-citation><mixed-citation xml:lang="en">Keller S, König AK, Marmé F, et al. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Letters. 2009;278(1):73-81. doi: 10.1016/j.canlet.2008.12.028</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Rupp AK, Rupp C, Keller S, et al. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecologic Oncology. 2011;122(2):437-446. doi: 10.1016/j.ygyno.2011.04.035</mixed-citation><mixed-citation xml:lang="en">Rupp AK, Rupp C, Keller S, et al. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecologic Oncology. 2011;122(2):437-446. doi: 10.1016/j.ygyno.2011.04.035</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget. 2016;7(6):6521-6537. doi: 10.18632/oncotarget.6658</mixed-citation><mixed-citation xml:lang="en">Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget. 2016;7(6):6521-6537. doi: 10.18632/oncotarget.6658</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Vieira GV, Somera Dos Santos F, Lepique AP, et al. Proteases and HPV-Induced Carcinogenesis. Cancers (Basel). 2022;14(13):3038–3042. doi: 10.3390/cancers14133038</mixed-citation><mixed-citation xml:lang="en">Vieira GV, Somera Dos Santos F, Lepique AP, et al. Proteases and HPV-Induced Carcinogenesis. Cancers (Basel). 2022;14(13):3038–3042. doi: 10.3390/cancers14133038</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sharova N, Zakharova L. Multiple forms of proteasomes and their role in tumor fate. Recent Patents on Endocrine Metabolic Immune Drug Discovery. 2008;2:152–161. doi: 10.2174/187221408786241847</mixed-citation><mixed-citation xml:lang="en">Sharova N, Zakharova L. Multiple forms of proteasomes and their role in tumor fate. Recent Patents on Endocrine Metabolic Immune Drug Discovery. 2008;2:152–161. doi: 10.2174/187221408786241847</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Родоман ГВ, Сумеди ИР, Шалаева ТИ, Плеханова АС, Шарова НП, Астахова М. Новый тест дифференциальной диагностики доброкачественных и злокачественных опухолей щитовидной железы. Лечебное дело. 2015;(3):72–76. Режим доступа: https://cyberleninka.ru/article/n/novyy-test-differentsialnoy-diagnostiki-dobrokachestvennyh-i-zlokachestvennyh-opuholey-schitovidnoy-zhelezy</mixed-citation><mixed-citation xml:lang="en">Rodoman GV, Sumedi IR, Shalaeva TI, Plekhanova AS, Sharova NP, Astakhova M. A new test for the differential diagnosis of benign and malignant tumors of the thyroid gland. Medical business. 2015;3:72–76 (In Russ.). Available from: https://cyberleninka.ru/article/n/novyy-test-differentsialnoy-diagnostiki-dobrokachestvennyh-i-zlokachestvennyh-opuholey-schitovidnoy-zhelezy</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Колегова ЕС, Кондакова ИВ, Завьялов АА. Малые белки теплового шока и убиквитин-протеасомная система при злокачественных опухолях. Вопросы онкологии. 2016;3:401-405. doi: 10.37469/0507-3758-2016-62-3-401-405</mixed-citation><mixed-citation xml:lang="en">Kolegova ES, Kondakova IV, Zavyalov AA. Small heat shock proteins and the ubiquitin-proteasome system in malignant tumors. Issues of oncology. 2016;3:401-405. doi: 10.37469/0507-3758-2016-62-3-401-405</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Спирина ЛВ, Кондакова ИВ, Коломиец ЛА, Чернышова АЛ, Асадчикова ОН, Шарова НП, и др. Активность протеасом и их субъединичный состав при гиперпластических процессах и раке эндометрия. Опухоли женской репродуктивной системы. 2011;(4):64-67. doi: 10.17650/1994-4098-2011-0-4-64-67</mixed-citation><mixed-citation xml:lang="en">Spirina LV, Kondakova IV, Kolomiets LA, Chernyshova AL, Asadchikova ON, Sharova NP, et al. Activity of proteasomes and their subunit composition in hyperplastic processes and endometrial cancer. Tumors of the female reproductive system. 2011;(4):64-67. doi: 10.17650/1994-4098-2011-0-4-64-67</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gileva O, Libik T, Daurova F, Mudrova O, Tatiana R. Oral cancer awareness among aged patients with chronic oral mucosal diseases in Russian Federation. BIO Web of Conference. 2020;22(01027):7-9. doi: 10.1051/bioconf/20202201027</mixed-citation><mixed-citation xml:lang="en">Gileva O, Libik T, Daurova F, Mudrova O, Tatiana R. Oral cancer awareness among aged patients with chronic oral mucosal diseases in Russian Federation. BIO Web of Conference. 2020;22(01027):7-9. doi: 10.1051/bioconf/20202201027</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Peres MA, Macpherson LMD, Weyant RJ, Daly B, Venturelli R, Mathur MR, et al. Oral diseases: a global public health challenge. Lancet. 2019;394(10194):249-260. doi: 10.1016/S0140-6736(19)31146-8</mixed-citation><mixed-citation xml:lang="en">Peres MA, Macpherson LMD, Weyant RJ, Daly B, Venturelli R, Mathur MR, et al. Oral diseases: a global public health challenge. Lancet. 2019;394(10194):249-260. doi: 10.1016/S0140-6736(19)31146-8</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
